Novartis Snaps Up Xiidra Eye Drops in $5.3 Billion Deal

GALWAY, IRELAND--May 27, 2019--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Swiss pharmaceutical company Novartis International AG (NYSE:NVS) (Basel, Switzerland) has agreed a $5.3 billion deal to purchase a number of eye-disease medicines from Takeda Pharmaceutical (Osaka, Japan).

Within this article: Details $5.3 billion deal, impact of drug, current sales, direction of Novartis and Takeda, related sales